Presented by
Dmitry Tyrsin

Nominated by

FSBI V.A. Nasonova Research Institute of Rheumatology RAMS

 

TheraMAB has discovered a revolutionary monoclonal antibody for immunotherapy. Oncological and autoimmune diseases are classified as the most severe ones – life threatening and/or disabling – and still represent a serious unsolved social and medical problem all over the world. We develope an innovative, potentially highly effective and broadly applicable immunotherapeutic monoclonal antibody that, by its unique capacity to selectively modulate the activity of T-regulatory cells, may provide new treatment options for major diseases in the field of autoimmunity and cancer.

More Venture Finalists

All Venture Finalists